

# GESTATIONAL DIABETES MELLITUS

Dr. Ghavami

# DIABETES IN PREGNANCY

- ▶ The **rise** in **GDM** and **type 2 diabetes** in **parallel** with **obesity** both in the U.S. and worldwide is of particular concern.
- ▶ Both **type 1** diabetes and **type 2** diabetes **confer** significantly greater **maternal and fetal risk** than **GDM**, with some differences according to type of diabetes as outlined below.

- ▶ In general, **specific risks of uncontrolled diabetes** in **pregnancy** include spontaneous abortion, fetal anomalies, preeclampsia, fetal demise, macrosomia, neonatal hypoglycemia, and neonatal hyperbilirubinemia ,among others.
- ▶ In addition, **diabetes** in **pregnancy** may **increase** the **risk** of **obesity** and **type 2 diabetes** in offspring later in life

## OUTLINE:-

- ▶ DEFINITION
- ▶ IMPORTANCE
- ▶ PREGNANCY - A DIABETOGENIC STATE
- ▶ WHEN DOES GESTATIONAL DIABETES DEVELOP?
- ▶ WHEN SHOULD WE DO SCREENING?
- ▶ WHAT ARE THE SCREENING TESTS?

## DEFINITION:-

- ▶ **Gestational diabetes** is defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy (American College of Obstetricians and Gynecologists, 2013).
- ▶ Therefore, it may include women with pre - existing but previously unrecognized diabetes.
- ▶ Since it occurs in the later half of pregnancy, it doesn't have any effect on organogenesis.
- ▶ The main problem with gestational diabetes is **macroomia** which usually reverts to normal following delivery.

## IMPORTANCE

- ▶ Use of the term gestational diabetes has been encouraged to communicate the need for increased surveillance and to stimulate women to seek further testing postpartum.
- ▶ The most important perinatal correlate is excessive fetal growth, which may result in both maternal and fetal birth trauma.
- ▶ The likelihood of fetal death with appropriately treated gestational diabetes is not different from that in the general population.
- ▶ Importantly, more than half of women with gestational diabetes ultimately develop overt diabetes in the ensuing 20 years

# PREVALENCE

- ▶ The prevalence of gestational diabetes as traditionally defined is **at least 2 percent**, and as **high as 25 percent** in some reports.
- ▶ The **prevalence varies** worldwide and among **racial** and ethnic groups, generally in step with the **prevalence of type 2 diabetes**.
- ▶ Prevalence also **varies** because of **differences** in **screening practices** (universal versus selective screening), **population characteristics** (eg, average **age** and body mass index [**BMI**] of pregnant women), **testing method**, and **diagnostic criteria**.
- ▶ Prevalence has been **increasing over time**, possibly related to **increases** in mean maternal **age** and **weight**.

# WHY PREGNANCY IS A DIABETOGENIC STATE?

- ▶ Pregnancy is a state of physiological **Insulin Resistance** especially in the second half.
- ▶ Estrogen, Progesterone and Human Placental Lactogen act as insulin antagonists causing insulin resistance.
- ▶ HPL → LIPOLYSIS → FREE FATY ACIDS → INSULIN RESISTANCE
- ▶ Plasma Cortisol also increase leading to Insulin Resistance.
- ▶ As a result pancreas produce more insulin and plasma glucose levels fall.
- ▶ *Pregnancy is characterized by fasting hypoglycemia and postprandial hyperglycemia.*

- ▶ In the fasting state there is hypoglycemia, decreased amino acids, and increased triglycerides breaking down into free fatty acids and ketone bodies.
- ▶ When fasting is prolonged, these all are exaggerated and ketosis appears.
- ▶ This pregnancy - induced switch in fuels from glucose to lipids has been described as **accelerated starvation**.

## WHEN DOES GESTATIONAL DIABETES DEVELOP?

- ▶ GDM develops when a stage is reached, when the pancreas despite the increased insulin production cannot counter the insulin resistance caused by the pregnancy hormones.
- ▶ GDM usually occurs in women with poor pancreatic reserve and insulin resistance such as those with polycystic ovary syndrome or a family history of diabetes.
- ▶ *It usually appears after 24 weeks of pregnancy.*

## Fifth International Workshop-Conference on Gestational Diabetes: Recommended Screening Strategy Based on Risk Assessment for Detecting Gestational Diabetes (GDM)


- ▶ GDM risk assessment: should be ascertained at the first prenatal visit.
- ▶ Low Risk: Blood glucose testing not routinely required if all the following are present:
  - (i) Member of an ethnic group with a low prevalence of GDM
  - (ii) No known diabetes in first-degree relatives
  - (iii) Age < 25 years
  - (iv) Weight normal before pregnancy
  - (v) Weight normal at birth
  - (vi) No history of abnormal glucose metabolism
  - (vii) No history of poor obstetrical outcome
- ▶ Average Risk: Perform screening test between 24 to 28 weeks using either:  
Two-step procedure: 50-g oral glucose challenge test (GCT), followed by a

A diagnostic 100-g OGTT for those meeting the threshold value in the GCT.

One-step procedure: diagnostic 100-g OGTT performed on all subjects.

- ▶ High Risk: Perform screening test as soon as possible, using the procedures described above, if one or more of these factors are present:
  - (i) Severe obesity
  - (ii) Strong family history of type 2 diabetes
  - (iii) Previous history of GDM, impaired glucose metabolism, or glycosuria
  - (iv) If GDM is not diagnosed, screening should be repeated at 24 to 28 weeks' gestation or at any time symptoms or signs suggest hyperglycemia

# Gestational Diabetes Mellitus - Screening Guidelines



# THRESHOLD VALUES FOR DIAGNOSING GDM

Plasma glucose	Glucose concentration Threshold		Above threshold (%) cumulative
	mmol/L	mg/dl	
Fasting	5.1	92	5.6
1 hour OGTT	10.0	180	14.0
2 hour OGTT	8.5	153	16.1

One or more of these values must be equaled or exceeded for the diagnosis of gestational diabetes.

# THE SCREENING TESTS....

▶ There are two approaches:-

1. **SINGLE STEP APPROACH**

2. **TWO STEP APPROACH**

▶ This Single Step Approach was greatly influenced by results of the Hypoglycemia and Pregnancy Outcomes (HAPO) Study. Although the ADA adopted this new scheme, the American College of Obstetricians and Gynecologists (2013) declined to endorse the single 75-gram oral glucose tolerance test.

▶ Instead, the College continues to recommend a two-step approach to screen and diagnose gestational diabetes.

## SINGLE STEP APPROACH

- ▶ Here the patient is given 75g of oral glucose without prior 50g glucose challenge test.
- ▶ The test should be performed in the morning after an overnight fast of at least 8 hr but not more than 14 hr and after at least 3 days of unrestricted diet ( $\geq 150$  g/d) and physical activity.
- ▶ Fasting and 2hr values are estimated.

## TWO STEP APPROACH

- ▶ The recommended two-step approach begins with either universal or risk-based selective screening using a 50-g, 1-hour oral glucose challenge test.
- ▶ This 50-g screening test is followed by a diagnostic 100-g, 3-hour oral glucose tolerance test (OGTT) if screening results meet or exceed a predetermined plasma glucose concentration.
- ▶ The plasma glucose level is measured 1 hour after a 50-g oral glucose load without regard to the time of day or time of last meal.
- ▶ The American College of Obstetricians and Gynecologists (2013) recommends using either 135 or 140 mg/dL as the 50-g screen threshold.
- ▶ In the 100g OGTT, the woman should have been on an unrestricted diet for the previous 3 days and fasting overnight.
- ▶ The fasting, 1 hour, 2 hour and 3 hour values are estimated.

# IN SHORT...

## 2 Approaches for Diagnosing Gestational Diabetes Mellitus (GDM)

AACE- and ADA-recommended	1-step 75-g 2-hour oral glucose tolerance test (OGTT) <sup>1,2</sup> or
ACOG-recommended	2 steps: a 50-g 1-hour glucose challenge test (GCT), followed by a 100-g 3-hour OGTT (if necessary) <sup>1</sup>

## GDM Diagnostic Criteria for OGTT Testing

	75-g 2-hour <sup>†</sup>	100-g 3-hour*
Fasting plasma glucose (FPG)	92 mg/dL (5.1 mmol/L) <sup>2</sup>	95 mg/dL (5.3 mmol/L) <sup>2</sup>
1-hour post-challenge glucose	180 mg/dL (10.0 mmol/L) <sup>2</sup>	180 mg/dL (10.0 mmol/L) <sup>2</sup>
2-hour post-challenge glucose	153 mg/dL (8.5 mmol/L) <sup>2</sup>	155 mg/dL (8.6 mmol/L) <sup>2</sup>
3-hour post-challenge glucose		140 mg/dL (7.8 mmol/L) <sup>2</sup>

<sup>†</sup>A positive diagnosis requires that test results satisfy any one of these criteria

\*A positive diagnosis requires that 2 thresholds are met or exceeded

# Adverse outcomes

- ▶ **Adverse outcomes** include:
- ▶ Preeclampsia
- ▶ Hydramnios
- ▶ Fetal macrosomia
- ▶ Fetal organomegaly (hepatomegaly, cardiomegaly)
- ▶ Birth trauma
- ▶ Operative delivery
- ▶ Perinatal mortality
- ▶ **Neonatal** respiratory problems and metabolic **complications** (hypoglycemia, hyperbilirubinemia, hypocalcemia, erythremia)

# RISK FACTORS FOR DIABETES DURING PREGNANCY

- A **family history** of diabetes, **especially** in **first degree** relatives
- **Prepregnancy weight**  $\geq 110$  percent of **ideal body weight** or **body mass index**  $>30$  kg/m<sup>2</sup>, significant weight gain in early adulthood and between pregnancies, or excessive gestational weight gain
- **Age**  $>25$  years
- **Previous delivery** of a **baby**  $>9$  pounds [4.1 kg]
- Personal **history** of **impaired glucose tolerance**
- Member of an **ethnic group** with higher than the background rate of type 2 diabetes (eg, Hispanic-American, African-American, Native American, South or East Asian, Pacific Islander)

# RISK FACTORS FOR DIABETES DURING PREGNANCY

- Previous unexplained perinatal loss or birth of a malformed infant
- Maternal birthweight >9 pounds [4.1 kg] or <6 pounds [2.7 kg]
- Glycosuria at the first prenatal visit
- Polycystic ovary syndrome
- Current use of glucocorticoids
- Essential hypertension or pregnancy-related hypertension
- Metabolic syndrome

# BENEFITS AND HARMS OF SCREENING

- ▶ The **benefit** of **screening** is that **identifying** pregnant women with **diabetes** followed by **appropriate therapy** can **decrease fetal and maternal morbidity**, particularly **macrosomia**, **shoulder dystocia**, and **preeclampsia**.

# Glucose monitoring and glycemic targets

## *Self-monitoring of blood glucose*

- ▶ 3.1. We recommend **self-monitoring** of blood glucose in **all pregnant women** with **gestational** or **overt** diabetes and suggest testing **before** and either **1 or 2 hours after** the start of **each meal** (choosing the postmeal time when it is estimated that peak postprandial blood glucose is most likely to occur) and, as indicated, at **bedtime** and **during the night**.

## *Management of elevated blood glucose*

- ▶ 2.3b. We recommend that the **initial treatment** of **gestational diabetes** should consist of medical **nutrition** therapy and daily **moderate exercise** for **30 minutes or more**.
- ▶ 2.3c. We recommend using blood glucose-lowering **pharmacological therapy** if **lifestyle therapy is insufficient** to maintain normoglycemia in women with gestational diabetes.

# Glucose Monitoring

- ▶ Reflecting this physiology, **fasting** and **postprandial monitoring** of blood glucose is recommended to achieve metabolic control in **pregnant women** with diabetes.
- ▶ **Preprandial testing** is also recommended for women with **preexisting diabetes** using insulin pumps or basal bolus therapy, so that **premeal rapidacting** insulin dosage can be **adjusted**.
- ▶ **Postprandial monitoring** is associated with **better glycemic control** and **lower risk of preeclampsia**.

- ▶ Similar to the **targets** recommended by the American College of Obstetricians and Gynecologists, the **ADA-recommended** targets for women with **type 1** or **type 2 diabetes** (the same as for **GDM**; described below) are as follows:
  - ▶ ○ **Fasting** = < **95** mg/dL (5.3 mmol/L) and either
  - ▶ ○ **One-hour** postprandial = < **140** mg/dL (7.8 mmol/L) or
  - ▶ ○ **Two-hour** postprandial = < **120** mg/dL (6.7 mmol/L).
- ▶ In **practice**, it may be **challenging** for women with **type 1 diabetes** to **achieve these targets without hypoglycemia**, particularly women with a history of recurrent hypoglycemia or hypoglycemia unawareness.

# A1C in Pregnancy

- ▶ Observational studies show the **lowest rates of adverse fetal outcomes** in **association** with **A1C <6-6.5%** (42-48 mmol/mol) **early in gestation**.
- ▶ Clinical trials have not evaluated the risks and benefits of achieving these targets, and treatment goals should account for the **risk of maternal hypoglycemia** in setting an **individualized target** of **<6%** (42 mmol/mol) to **<7%** (53 mmol/mol).
- ▶ Due to physiological **increases** in **red blood cell turnover**, **A1C** levels **fall** during normal **pregnancy**.
- ▶ although A1C may be **useful**, it should be used as a **secondary measure** of glycemic control, **after self-monitoring** of blood glucose.

- ▶ In the **second and third trimesters**, **A1C < 6%** (42 mmol/mol) has the **lowest risk** of **large-for-gestational-age infants**, whereas other **adverse outcomes** increase with **A1C > 6.5%** (48 mmol/mol).
- ▶ Taking all of this into account, a **target** of **6-6.5%** (42-48 mmol/mol) is recommended **but < 6%** (42 mmol/mol) may be **optimal** as pregnancy progresses.
- ▶ **These levels** should be **achieved without hypoglycemia**, which, in addition to the usual adverse sequelae, may **increase the risk of low birth weight**.

## *Postpartum care*

- ▶ We recommend that a **2-hour, 75-gOGTT** should be undertaken **6 to 12 weeks after delivery** in women with **gestational diabetes** to rule out prediabetes or diabetes.
- ▶ We suggest **blood glucose-lowering medication** should be **discontinued immediately after delivery** for women with **gestational diabetes unless overt diabetes** is suspected in which case the decision to continue such medication should be made on a case-by-case basis.

Thanks for attention